Back

Empagliflozin attenuates pulmonary vascular hemodynamic progression and improves right ventricular adaptation in overcirculation-induced pulmonary hypertension

28 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Pulmonary hypertension: pre-clinical Pharmacotherapy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Ana Garcia-Alvarez

Hospital Clinic, University of Barcelona, Barcelona (Spain)

5 More presentations in this session

Presentation thumbnail
Insulin resistance genetic susceptibility drives pulmonary arterial hypertension through monocyte metabolic reprogramming and immune dysregulation
Mr S. Hou (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Interleukin-22–STAT3 Signaling Preserves Structural Integrity in the Pressure-Overloaded Right Ventricle
Doctor K. Shibao (Kurume, JP)
Abstract Slides Video
Presentation thumbnail
Prophylactic ranolazine and trimetazidine attenuate right ventricular dysfunction and improve exercise capacity in experimental pulmonary hypertension
Doctor A. Oz (Istanbul, TR) Miss S. Asal (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Myo-inositol trispyrophosphate improves oxygen delivery and right ventricular function in rat pressure overload model
Doctor M. Maczewski (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Targeting the PSMB9–NGAL/MMP9 Axis: a novel neutrophil-driven mechanism and precision target for vascular remodeling in PAH
Associate Professor X. He (Guangzhou, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Pulmonary hypertension: pre-clinical

The Event

Event poster

ESC Congress 2026

28 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Prophylactic dapagliflozin attenuates pulmonary vascular remodelling, preserves right ventricular function, and maintains exercise capacity in a monocrotaline-induced pulmonary hypertension rat model
29 August 2026
thumbnail
Congress Presentation
Acute effect of empagliflozin on echocardiographic parameter in de novo heart failure: a secondary analysis of the EMPAG-HF trial
12 May 2024
thumbnail
Congress Session
Pulmonary hypertension and right ventricular
31 August 2026
thumbnail
Congress Presentation
Right ventricular diastolic dysfunction across experimental disease models: unpacking diversity beyond pulmonary hypertension - a systematic review
30 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources